{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:50Z","timestamp":1789712810978,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12072-018-9896-4","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T08:12:12Z","timestamp":1537431132000},"page":"500-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A changing paradigm: management and treatment of the HCV\/HIV-co-infected patient"],"prefix":"10.1007","volume":"12","author":[{"given":"Ameer","family":"Abutaleb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"9896_CR1","unstructured":"Hepatitis C [Internet].; 2017 []. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c . Accessed 12 July 2018."},{"issue":"3","key":"9896_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12072-018-9873-y","volume":"12","author":"A Abutaleb","year":"2018","unstructured":"Abutaleb A, Kottilil S, Wilson E. Glecaprevir\/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int. 2018;12(3):214\u201322.","journal-title":"Hepatol Int"},{"key":"9896_CR3","unstructured":"HIV and hepatitis coinfections [Internet]. 2017. http:\/\/www.who.int\/hiv\/topics\/hepatitis\/en\/ . Accessed 12 July 2018."},{"issue":"4","key":"9896_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivirc group. Hepatology. 1999;30(4):1054\u20138.","journal-title":"Hepatology"},{"issue":"9","key":"9896_CR5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/cid\/ciw531","volume":"63","author":"MB Klein","year":"2016","unstructured":"Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, III Lo Re V, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in north america from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63(9):1160\u20137.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"9896_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1086\/518251","volume":"195","author":"JT Blackard","year":"2007","unstructured":"Blackard JT, Hiasa Y, Smeaton L, Jamieson DJ, Rodriguez I, Mayer KH, et al. Compartmentalization of hepatitis C virus (HCV) during HCV\/HIV coinfection. J Infect Dis. 2007;195(12):1765\u201373.","journal-title":"J Infect Dis"},{"issue":"5","key":"9896_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2893.2008.00970.x","volume":"15","author":"JT Blackard","year":"2008","unstructured":"Blackard JT, Sherman KE. HCV\/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat. 2008;15(5):323\u201330.","journal-title":"J Viral Hepat"},{"issue":"5","key":"9896_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/cid\/ciq199","volume":"52","author":"JT Blackard","year":"2011","unstructured":"Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, et al. HIV mono-infection is associated with FIB-4\u2014A noninvasive index of liver fibrosis\u2014in women. Clin Infect Dis. 2011;52(5):674\u201380.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9896_CR9","doi-asserted-by":"publisher","first-page":"e52720","DOI":"10.1371\/journal.pone.0052720","volume":"8","author":"SH Han","year":"2013","unstructured":"Han SH, Kim SU, Kim CO, Jeong SJ, Park JY, Choi JY, et al. Abnormal liver stiffness assessed using transient elastography (Fibroscan(R)) in HIV-infected patients without HBV\/HCV coinfection receiving combined antiretroviral treatment. PLoS One. 2013;8(1):e52720.","journal-title":"PLoS One"},{"issue":"7","key":"9896_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/liv.12159","volume":"33","author":"H Hasson","year":"2013","unstructured":"Hasson H, Merli M, Galli L, Gallotta G, Carbone A, Messina E, et al. Non-invasive fibrosis biomarkers\u2014APRI and forns\u2014are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. Liver Int. 2013;33(7):1113\u201320.","journal-title":"Liver Int"},{"issue":"1","key":"9896_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","volume":"44","author":"N Brau","year":"2006","unstructured":"Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44(1):47\u201355.","journal-title":"J Hepatol"},{"issue":"9397","key":"9896_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","volume":"362","author":"N Qurishi","year":"2003","unstructured":"Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362(9397):1708\u201313.","journal-title":"Lancet"},{"issue":"6","key":"9896_CR13","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.3390\/ijms15069184","volume":"15","author":"CM Mastroianni","year":"2014","unstructured":"Mastroianni CM, Lichtner M, Mascia C, Zuccala P, Vullo V. Molecular mechanisms of liver fibrosis in HIV\/HCV coinfection. Int J Mol Sci. 2014;15(6):9184\u2013208.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"9896_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1086\/379738","volume":"188","author":"SR Vlahakis","year":"2003","unstructured":"Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis. 2003;188(10):1455\u201360.","journal-title":"J Infect Dis"},{"issue":"1","key":"9896_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/hep.510300147","volume":"30","author":"KF Yoong","year":"1999","unstructured":"Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology. 1999;30(1):100\u201311.","journal-title":"Hepatology"},{"issue":"2","key":"9896_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/hep.23679","volume":"52","author":"AC Tuyama","year":"2010","unstructured":"Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV\/hepatitis C virus-induced liver fibrosis. Hepatology. 2010;52(2):612\u201322.","journal-title":"Hepatology"},{"issue":"8","key":"9896_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1086\/378643","volume":"188","author":"N Munshi","year":"2003","unstructured":"Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis. 2003;188(8):1192\u2013204.","journal-title":"J Infect Dis"},{"issue":"6","key":"9896_CR18","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/hep.22890","volume":"49","author":"F Hong","year":"2009","unstructured":"Hong F, Tuyama A, Lee TF, Loke J, Agarwal R, Cheng X, et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology. 2009;49(6):2055\u201367.","journal-title":"Hepatology"},{"issue":"5","key":"9896_CR19","doi-asserted-by":"publisher","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","volume":"285","author":"RF Schwabe","year":"2003","unstructured":"Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol. 2003;285(5):G949\u201358.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"9896_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/gut.2008.163287","volume":"59","author":"R Bruno","year":"2010","unstructured":"Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut. 2010;59(4):513\u201320.","journal-title":"Gut"},{"issue":"3","key":"9896_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/jhep.2001.22761","volume":"33","author":"E Efsen","year":"2001","unstructured":"Efsen E, Bonacchi A, Pastacaldi S, Valente AJ, Wenzel UO, Tosti-Guerra C, et al. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology. 2001;33(3):713\u201321.","journal-title":"Hepatology"},{"issue":"2","key":"9896_CR22","first-page":"423","volume":"152","author":"F Marra","year":"1998","unstructured":"Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998;152(2):423\u201330.","journal-title":"Am J Pathol"},{"issue":"7","key":"9896_CR23","first-page":"1858","volume":"119","author":"E Seki","year":"2009","unstructured":"Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119(7):1858\u201370.","journal-title":"J Clin Invest"},{"issue":"1","key":"9896_CR24","doi-asserted-by":"publisher","first-page":"e53992","DOI":"10.1371\/journal.pone.0053992","volume":"8","author":"L Ochoa-Callejero","year":"2013","unstructured":"Ochoa-Callejero L, Perez-Martinez L, Rubio-Mediavilla S, Oteo JA, Martinez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 2013;8(1):e53992.","journal-title":"PLoS One"},{"issue":"4","key":"9896_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jhep.2011.04.023","volume":"55","author":"S Affo","year":"2011","unstructured":"Affo S, Bataller R. RANTES antagonism: a promising approach to treat chronic liver diseases. J Hepatol. 2011;55(4):936\u20138.","journal-title":"J Hepatol"},{"issue":"11","key":"9896_CR26","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1172\/JCI41732","volume":"120","author":"ML Berres","year":"2010","unstructured":"Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010;120(11):4129\u201340.","journal-title":"J Clin Invest"},{"issue":"8","key":"9896_CR27","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s10096-012-1546-5","volume":"31","author":"J Macias","year":"2012","unstructured":"Macias J, Viloria MM, Rivero A, de los Santos I, Marquez M, Portilla J, et al. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV\/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2012;31(8):2083\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"9896_CR28","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1074\/jbc.M110.168286","volume":"286","author":"W Lin","year":"2011","unstructured":"Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, et al. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem. 2011;286(4):2665\u201374.","journal-title":"J Biol Chem"},{"issue":"4","key":"9896_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/QAI.0000000000001524","volume":"76","author":"AL French","year":"2017","unstructured":"French AL, Martin JW, Evans CT, Peters M, Kessaye SG, Nowicki M, et al. Macrophage activation and the tumor necrosis factor cascade in hepatitis C disease progression among HIV-infected female participating in the women\u2019s interagency HIV study. J Acquir Immune Defic Syndr. 2017;76(4):438\u201344.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"9896_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362\u201371.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"15","key":"9896_CR31","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","volume":"166","author":"R Weber","year":"2006","unstructured":"Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:a: D study. Arch Intern Med. 2006;166(15):1632\u201341.","journal-title":"Arch Intern Med"},{"issue":"11","key":"9896_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrgastro.2013.146","volume":"10","author":"WZ Mehal","year":"2013","unstructured":"Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10(11):637\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"9896_CR33","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1128\/JVI.02202-06","volume":"81","author":"N Alatrakchi","year":"2007","unstructured":"Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ. Hepatitis C virus (HCV)-specific CD8\u2009+\u2009cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol. 2007;81(11):5882\u201392.","journal-title":"J Virol"},{"issue":"7","key":"9896_CR34","doi-asserted-by":"publisher","first-page":"d793","DOI":"10.2741\/A812","volume":"1","author":"AM Gressner","year":"2002","unstructured":"Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;1(7):d793\u2013807.","journal-title":"Front Biosci"},{"issue":"8","key":"9896_CR35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/135965350801300815","volume":"13","author":"T Reiberger","year":"2008","unstructured":"Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther. 2008;13(8):969\u201376.","journal-title":"Antivir Ther"},{"issue":"37","key":"9896_CR36","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","volume":"24","author":"J Zavadil","year":"2005","unstructured":"Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764\u201374.","journal-title":"Oncogene"},{"issue":"2","key":"9896_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/path.2276","volume":"214","author":"V Appay","year":"2008","unstructured":"Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231\u201341.","journal-title":"J Pathol"},{"issue":"5","key":"9896_CR38","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/QAI.0b013e31820ef408","volume":"56","author":"MM Oca Arjona de","year":"2011","unstructured":"de Oca Arjona MM, Marquez M, Soto MJ, Rodriguez-Ramos C, Terron A, Vergara A, et al. Bacterial translocation in HIV-infected patients with HCV cirrhosis: implication in hemodynamic alterations and mortality. J Acquir Immune Defic Syndr. 2011;56(5):420\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"9896_CR39","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1053\/j.gastro.2011.06.063","volume":"141","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141(4):1220\u201330.","journal-title":"Gastroenterology"},{"issue":"6","key":"9896_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/COH.0b013e32834bbc71","volume":"6","author":"EE Page","year":"2011","unstructured":"Page EE, Nelson M, Kelleher P. HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Curr Opin HIV AIDS. 2011;6(6):472\u20137.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"9896_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/hiv.12502","volume":"18","author":"A Mena","year":"2017","unstructured":"Mena A, Meijide H, Rodriguez-Osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med. 2017;18(9):685\u20139.","journal-title":"HIV Med"},{"issue":"7\u20138","key":"9896_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/20477724.2016.1253532","volume":"110","author":"D Behzadpour","year":"2016","unstructured":"Behzadpour D, Ahmadi Vasmehjani A, Mousavi Nasab SD, Ahmadi NA, Baharlou R. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. Pathog Glob Health. 2016;110(7\u20138):310\u20135.","journal-title":"Pathog Glob Health"},{"issue":"8","key":"9896_CR43","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/dmd.117.079038","volume":"46","author":"KL Garrison","year":"2018","unstructured":"Garrison KL, German P, Mogalian E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018;46(8):1212\u20131225.","journal-title":"Drug Metab Dispos."},{"issue":"2","key":"9896_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1128\/AAC.49.2.643-649.2005","volume":"49","author":"M Regazzi","year":"2005","unstructured":"Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother. 2005;49(2):643\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"9896_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1055\/s-2007-991511","volume":"27","author":"G Szabo","year":"2007","unstructured":"Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007;27(4):339\u201350.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"9896_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.21672","volume":"46","author":"K Matsuzaki","year":"2007","unstructured":"Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46(1):48\u201357.","journal-title":"Hepatology"},{"issue":"5","key":"9896_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/505708","volume":"194","author":"A Balasubramanian","year":"2006","unstructured":"Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis. 2006;194(5):670\u201381.","journal-title":"J Infect Dis"},{"issue":"3","key":"9896_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jhep.2013.04.029","volume":"59","author":"A Glassner","year":"2013","unstructured":"Glassner A, Eisenhardt M, Kokordelis P, Kramer B, Wolter F, Nischalke HD, et al. Impaired CD4(+) T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV\/HCV patients. J Hepatol. 2013;59(3):427\u201333.","journal-title":"J Hepatol"},{"key":"9896_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2172-13-15","volume":"13","author":"J Qu","year":"2012","unstructured":"Qu J, Zhang Q, Li Y, Liu W, Chen L, Zhu Y, et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol. 2012;13:15 (2172-13-15).","journal-title":"BMC Immunol"},{"issue":"246","key":"9896_CR50","doi-asserted-by":"publisher","first-page":"246ra98","DOI":"10.1126\/scitranslmed.3008195","volume":"6","author":"KE Sherman","year":"2014","unstructured":"Sherman KE, Guedj J, Shata MT, Blackard JT, Rouster SD, Castro M, et al. Modulation of HCV replication after combination antiretroviral therapy in HCV\/HIV co-infected patients. Sci Transl Med. 2014;6(246):246ra98.","journal-title":"Sci Transl Med"},{"issue":"11","key":"9896_CR51","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/cid\/ciu675","volume":"59","author":"D Dieterich","year":"2014","unstructured":"Dieterich D, Rockstroh JK, Orkin C, Gutierrez F, Klein MB, Reynes J, et al. Simeprevir (TMC435) with pegylated interferon\/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014;59(11):1579\u201387.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9896_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353\u201361.","journal-title":"JAMA"},{"issue":"9973","key":"9896_CR53","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","volume":"385","author":"JM Molina","year":"2015","unstructured":"Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098\u2013106.","journal-title":"Lancet"},{"issue":"12","key":"9896_CR54","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232\u20139.","journal-title":"JAMA"},{"issue":"8","key":"9896_CR55","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705\u201313.","journal-title":"N Engl J Med"},{"issue":"9973","key":"9896_CR56","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087\u201397.","journal-title":"Lancet"},{"issue":"8","key":"9896_CR57","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327.","journal-title":"Lancet HIV"},{"issue":"8","key":"9896_CR58","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"9896_CR59","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223\u201331.","journal-title":"JAMA"},{"issue":"4","key":"9896_CR60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/jiw597","volume":"215","author":"D Wyles","year":"2017","unstructured":"Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, et al. TURQUOISE-I Part 1b: ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis. 2017;215(4):599\u2013605.","journal-title":"J Infect Dis"},{"issue":"1","key":"9896_CR61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/cid\/cix260","volume":"65","author":"D Wyles","year":"2017","unstructured":"Wyles D, Brau N, Kottilil S, Daar ES, Ruane P, Workowski K, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6\u201312.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9896_CR62","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/S0168-8278(17)30467-1","volume":"66","author":"J Rockstroh","year":"2017","unstructured":"Rockstroh J, Lacombe K, Viani R, Orkin C, Wyles D, Luetkemeyer A, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. J Hepatol. 2017;66(1):S102\u20133.","journal-title":"J Hepatol"},{"issue":"1","key":"9896_CR63","first-page":"132A","volume":"64","author":"S Zeuzem","year":"2016","unstructured":"Zeuzem S, Feld JJ, Wang S, Bourli\u00e8re M, Wedemeyer H, Gane EJ, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493\/ABT-530 in patients with chronic HCV genotype 1 infection. Hepatology. 2016;64(1):132A\u20133A.","journal-title":"Hepatology"},{"key":"9896_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2017.07.001","volume":"62","author":"G Bruno","year":"2017","unstructured":"Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell\u2019Acqua R, Milano E, et al. HCV mono-infected and HIV\/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis. 2017;62:64\u201371.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"9896_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/QAI.0000000000000516","volume":"68","author":"M Rodriguez-Torres","year":"2015","unstructured":"Rodriguez-Torres M, Gaggar A, Shen G, Kirby B, Svarovskaia E, Brainard D, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. J Acquir Immune Defic Syndr. 2015;68(5):543\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"9896_CR66","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1086\/593102","volume":"47","author":"E Tedaldi","year":"2008","unstructured":"Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis. 2008;47(11):1468\u201375.","journal-title":"Clin Infect Dis"},{"key":"9896_CR67","unstructured":"Interaction Checker [Internet]. 2018. https:\/\/www.hep-druginteractions.org\/ . Accessed 12 July 2018."},{"issue":"7\u20138","key":"9896_CR68","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1016\/S0041-1345(01)02569-6","volume":"33","author":"P Stock","year":"2001","unstructured":"Stock P, Roland M, Carlson L, Freise C, Hirose R, Terrault N, et al. Solid organ transplantation in HIV-positive patients. Transpl Proc. 2001;33(7\u20138):3646\u20138.","journal-title":"Transpl Proc"},{"issue":"6","key":"9896_CR69","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/lt.23411","volume":"18","author":"NA Terrault","year":"2012","unstructured":"Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716\u201326.","journal-title":"Liver Transpl"},{"issue":"3","key":"9896_CR70","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jhep.2014.10.032","volume":"62","author":"JM Miro","year":"2015","unstructured":"Miro JM, Stock P, Teicher E, Duclos-Vallee JC, Terrault N, Rimola A. Outcome and management of HCV\/HIV coinfection pre- and post-liver transplantation. A 2015 update. J Hepatol. 2015;62(3):701\u201311.","journal-title":"J Hepatol"},{"issue":"3","key":"9896_CR71","first-page":"435","volume":"30","author":"ME Roland","year":"2016","unstructured":"Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS. 2016;30(3):435\u201344.","journal-title":"AIDS"},{"issue":"1","key":"9896_CR72","first-page":"38","volume":"11","author":"P Fitzmorris","year":"2015","unstructured":"Fitzmorris P, Singal AK. Surveillance and diagnosis of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2015;11(1):38\u201346.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"9896_CR73","unstructured":"Guidelines, version 9.0 [Internet]. 2017. http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf . Accessed 12 July 2018."},{"issue":"4","key":"9896_CR74","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir\u2013pibrentasvir for 8 or 12\u00a0Weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354\u201369.","journal-title":"N Engl J Med"},{"issue":"5","key":"9896_CR75","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"9896_CR76","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(2):430\u201341.","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9896-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:03:27Z","timestamp":1751933007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9896-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["9896"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9896-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Sherman has received grants and contracts (paid to institution) from AbbVie, BMS, Gilead, and Merck. He has served on advisory boards for Abbott Laboratories, and Merck on Data Monitoring boards for MedPace and Watermark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable for a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable for a review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}